Difference between revisions of "Factor VIII, human"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
m
Line 23: Line 23:
 
[[Category:Intravenous medications]]
 
[[Category:Intravenous medications]]
  
 +
[[Category:Inherited coagulopathy medications]]
 
[[Category:Hematology medications]]
 
[[Category:Hematology medications]]
 
[[Category:Hemostasis medications]]
 
[[Category:Hemostasis medications]]
 
[[Category:Coagulation factors]]
 
[[Category:Coagulation factors]]

Revision as of 14:22, 22 August 2018

General information

Class/mechanism: Factor VIII; replaces the missing clotting factor VIII that is required for hemostasis in patients with hemophilia A.
Please choose from the products below to find specific drug/manufacturer information:

Route: IV
Extravasation: no information

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.

Diseases for which it is used

  • Hemophilia A

Also known as

  • Generic name: coagulation factor 8
  • Brand names: Hemofil-M, Koate-DVI, Koate-HP, Monarc-M, Monoclate-P

References